Professional and Linguistic Assessments Board (PLAB) Practice Exam

What should a healthcare provider monitor for in a patient receiving Isoniazid therapy?

1. Gout symptoms

2. Color vision changes

3. Signs of hepatotoxicity

4. Respiratory function

The correct answer is: Signs of hepatotoxicity

Monitoring for signs of hepatotoxicity in a patient receiving Isoniazid therapy is essential due to the risk of liver damage associated with this medication. Isoniazid is known to potentially cause liver injury, which can manifest in various ways, such as elevated liver enzymes, jaundice, fatigue, and abdominal pain. Regular assessment of liver function tests is therefore fundamental in identifying any adverse effects early and ensuring patient safety. While the other options present valid considerations in general patient care and monitoring, they are not specifically associated with Isoniazid therapy. For instance, monitoring for gout symptoms is not directly relevant to the effects of Isoniazid. Color vision changes are typically linked to other medications, such as those used to treat tuberculosis, but not specifically to Isoniazid. Lastly, respiratory function is important to monitor in a patient with tuberculosis itself, but it is not a primary concern associated with Isoniazid treatment alone. Thus, the focus should be on the liver health of patients undergoing Isoniazid therapy.